- Savara reported third quarter 2026 results that showed a net loss of US$42.99 million and basic loss per share of US$0.17, compared with a net loss of US$29.56 million and loss per share of US$0.14 for the same period a year earlier.
- For the nine months to September 30, 2026, Savara's net loss reached US$120.5 million and basic loss per share was US$0.47, which highlights sustained cash burn that keeps funding needs and execution discipline firmly in focus for investors tracking the business.
- We will now look at how Savara's widening net losses might influence the broader investment narrative that investors are building around it.
Scan how Savara's widening losses compare with other specialist biotechs by reviewing a hand picked set of list of solid balance sheet and fundamentals (23 results) that may be better positioned to withstand prolonged cash burn.
What Is Savara's Investment Narrative?
Owning Savara is really about believing that a focused rare disease pipeline can eventually justify years of losses. Everything comes back to molgramostim and whether management can keep Phase 3 execution on track while funding an operation that currently generates no revenue and carries widening net losses. The latest quarterly figures, including a US$42.99 million loss for the third quarter and US$120.5 million for the first nine months of 2026, simply reinforce that this is still a pure cash out story.
In the short term, the bigger questions are not about this earnings print itself but about cash runway, potential financing and any pressure on trial timelines. The results highlight the cash burn, yet they do not signal a shift in clinical priorities or demand dynamics, since Savara is pre commercial. Analyst forecasts that point to strong expected revenue and earnings growth are only useful if the company can reach and monetize approval without diluting that upside too heavily.
That said, the picture becomes more complicated once you layer in ...
There's only one way to know the right time to buy, sell or hold Savara. Head to Simply Wall St's company report for the latest analysis of Savara's Fair Value.
Decide For Yourself
Don't just follow the ticker. Dig into the data and build a conviction that's truly your own.
- A great starting point for your Savara research is our analysis highlighting 1 key reward and 1 important warning sign that could impact your investment decision.
- See our latest analysis for Savara. The report includes a comprehensive fundamental analysis summarized in a single visual, the Snowflake, making it easy to evaluate Savara's overall financial health at a glance.
Looking For More Investment Ideas Beyond Savara?
Once you have formed a view on Savara, it can help to compare that thesis with opportunities across different styles, income profiles and balance sheet strengths using the broader Simply Wall St Screener.
- If you want income potential alongside resilience, start with a shortlist of reliable payers by reviewing 6 dividend fortresses that have been filtered for yield and balance sheet strength.
- For investors focused on value, widen your opportunity set by scanning 31 high quality undervalued stocks where quality fundamentals and pricing appear out of sync.
- If capital preservation matters most to you right now, concentrate your research on 29 resilient stocks with low risk scores that combine lower risk scores with more robust financial profiles.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com